Skip to content

8-KAccepted Nov 16, 7:20 AM ET

MapLight Therapeutics, Inc.: reports Q3 2026 results and updates presentation

MPLTMapLight Therapeutics, Inc.

Accepted (ET)

7:20 AM

Nov 16, 2026

Filed

Nov 16, 2026

Documents

40

Size

14.4 MB

Summary

MapLight Therapeutics, Inc.: reports Q3 2026 results and updates presentation

Updated

What happened On Nov 16, 2026, MapLight Therapeutics, Inc. issued a press release announcing its financial results for the 3rd quarter ended Sep 30, 2026. A copy of the press release was furnished as Exhibit 99.1 to the Current Report on Form 8-K.

On Nov 16, 2026, the company updated its corporate presentation for use in meetings with investors, analysts and others; the updated presentation is available on the company’s website and was furnished as Exhibit 99.2 to the Form 8-K.

Key details

  • Item 2.02 reported results of operations and financial condition via a press release dated Nov 16, 2026 covering the 3rd quarter ended Sep 30, 2026.
  • Item 7.01 disclosed an updated corporate presentation dated Nov 16, 2026, furnished as Exhibit 99.2 and available on the company’s website.
  • The Form 8-K was signed by Christopher A. Kroeger, M.D., Chief Executive Officer, and filed on Nov 16, 2026.

Why it may matter This Form 8-K reports Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure of an updated corporate presentation). A filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing